Industry
Biotechnology
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 8:04 pm
Portfolio Pulse from Benzinga Newsdesk
April 12, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 3:46 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 1:11 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 9:04 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Insights
February 29, 2024 | 10:15 am
Portfolio Pulse from Benzinga Insights
February 28, 2024 | 3:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.